Quarterly report [Sections 13 or 15(d)]

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.26.3
COMMITMENTS AND CONTINGENCIES (Details Narrative)
9 Months Ended
Oct. 04, 2023
USD ($)
Sep. 30, 2026
USD ($)
$ / shares
shares
Sep. 30, 2026
EUR (€)
shares
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Mar. 11, 2025
USD ($)
Mar. 04, 2025
USD ($)
Jan. 05, 2024
USD ($)
Sep. 30, 2019
USD ($)
Dec. 10, 2015
USD ($)
Common stock portion   $ 353,404   $ 442,844            
Prepaid expenses   $ 249,921     $ 226,198          
Compensation for services, description   As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a remuneration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a remuneration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month              
Total consideration amount   $ 743,971                
Accounts receivables   0     253,459          
Charles River Laboratories, Inc. [Member]                    
Outstanding debt balance   $ 28,936                
BICX Holding Company LLC [Member]                    
Common stock issued upon convertible debt | shares   2,227,575 2,227,575              
Convertible Promissory Note                 $ 4,160,000  
Total Interest Payment   $ 1,138,157                
Issuance price per share | $ / shares   $ 2.00                
Conversion agreement description   the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment              
Orange County Research Center [Member]                    
Payment of clinical services   $ 503,089                
Pellecome [Member]                    
Attorney's fees awarded   222,933                
Total cost and attorney's fees payment   235,886                
Settelment amount           $ 418,000        
Outstanding debt balance   $ 0                
Interest rate   10.00% 10.00%              
Pellecome [Member] | January 5, 2024 [Member]                    
Attorney's fees awarded $ 222,933 $ 332,503                
Judgment in favor of Pellecome   332,503                
Accrued interest   94,816                
Consultant [Member]                    
Monthly strategic advisory fee   7,500                
Cash portion   3,750                
Common stock portion   978                
Advisory board compensation   $ 17,000                
Advisory services agreement description   the Company is required to pay a monthly retainer fee of EUR 4,000 for the initial six-month period, consisting of EUR 2,000 payable in cash and EUR 2,000 payable in shares of the Company’s common stock the Company is required to pay a monthly retainer fee of EUR 4,000 for the initial six-month period, consisting of EUR 2,000 payable in cash and EUR 2,000 payable in shares of the Company’s common stock              
Common share issued for services | shares   3,000 3,000              
Renumeration amount   $ 1,417                
Monthly retainer fee converted | €     € 4,000              
Prepaid expenses   16,022                
Alpine Creek [Member]                    
Royalty amount due   91     91          
Total consideration amount   1,531,926     $ 1,531,926          
Accounts receivables                   $ 1,215,000
Payment received for services   $ 1,620,000                
Payable commitment description   On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale              
Payable per treatment sold                   $ 100
Profit holding percentage                   50.00%
Board of directors                    
Annual compensation               $ 200,000    
Cash received             $ 15,000      
Stock equivalent amount             $ 5,000